HK-660S

Phase 2Small molecule

CCuromeBiosciences

HK-660S is one of 41 small molecule programs targeting Sclerosing Cholangitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sclerosing CholangitisActive, not recruiting

Sclerosing CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Sclerosing Cholangitis

#DrugCompanyPhaseTrials

Vancocin

HHikma Pharmaceuticals LLC

Approved

9 2

Actigall

AbbVie

Approved

—3

Retin-a

VValeant Pharmaceuticals

Approved

—4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Mitosol

Zocor

1 7

Azulfidine

Pfizer

Phase 2

1 8

Iqirvo

Ipsen

Phase 2

1 9

Thalomid

Bristol-Myers Squibb

Phase 2

1 10

Ocaliva

IIntercept Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Sclerosing Cholangitis

NCT06975150

Clinical

Trials by Indication[1]

Sclerosing Cholangitis2 trials

Efficacy and Safety of HK-660S in the Treatment of Primary Sclerosing Cholangitis

Not yet recruiting·CCuromeBiosciences·Phase 2·NCT06975150·105 enrolled

Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis

Completed·CCuromeBiosciences·Phase 2·NCT05866809·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HK-660S. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HK-660S compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HK-660S. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CuromeBiosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCuromeBiosciences

HK-660S

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Sclerosing Cholangitis2 trials

References

Drug Info

Quick Facts

Related News